Results 181 to 190 of about 211,773 (281)

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Evaluating the Prevalence and Nature of Self-Employment in the Informal Economy: Evidence From a 27-Nation European Survey

European Spatial Research and Policy, 2012
Colin C. Williams, Sara Nadin, Jan Windebank   +2 more
doaj   +1 more source

In vitro antiproliferative activity on A549 and HT-29 cell lines and fatty acid profiling of Agaricus bresadolanus and A. hortensis. [PDF]

Naturwissenschaften
Alli H, Demir İ, Yeniocak S, Kivrak İ, Sarac N, Kaya E, Ugur A.   +6 more
europepmc   +1 more source

Mushroom Gastrostomy [PDF]

Seminars in Interventional Radiology, 2005
openaire   +2 more sources

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

The complete mitochondrial genome sequence of the angel-wing mushroom <i>Pleurocybella porrigens</i>. [PDF]

Mitochondrial DNA B Resour
Mitsukuni K, Watanabe N, Sekimata K, Zhang J, Ono A, Tanaka Y, Suzuki T.   +6 more
europepmc   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Characterization of Bioactive Compounds in Spent Mushroom Substrate: A Metabolomic Perspective on Its Untapped Potential. [PDF]

Foods
Zhang L, Cheah IK, Lu Y, Huang D, Loo AEK.   +4 more
europepmc   +1 more source

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J. Cooper, John Gordon, Catherine A. Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews, Nicholas M. Barnes   +10 more
wiley   +1 more source

Valorisation of spent mushroom substrate by secondary microbial fermentation. [PDF]

Appl Microbiol Biotechnol
Baker PW, Bragança R, Lloyd AJ, Charlton A.   +3 more
europepmc   +1 more source